Clinical trial design in brain metastasis: Approaches for a unique patient population

Current Oncology Reports

Volumn 14, Issue 1, 2012, Pages 91-96

  Peereboom, David M ^a  

^a CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

Author keywords

Adaptive randomization; Blood brain barrier; Brain metastasis; Chemobrain; Chemoprevention; Chemotherapy; Clinical trial design; Clinical trials; Leptomeningeal carcinomatosis; Patient advocacy; Pre irradiation chemotherapy; Primary prevention; Randomized phase 2; Secondary prevention; Stereotactic radiosurgery; Stratification; Systemic therapy; Whole brain radiation therapy

Indexed keywords

CAPECITABINE; FOTEMUSTINE; INIPARIB; IRINOTECAN; LAPATINIB; SUNITINIB; TRASTUZUMAB;

ARTICLE; BLOOD BRAIN BARRIER; BRAIN METASTASIS; BRAIN RADIATION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; FEASIBILITY STUDY; HIGH RISK PATIENT; HUMAN; MENINGOCELE; OUTCOME ASSESSMENT; PATIENT ADVOCACY; PRIMARY PREVENTION; QUALITY OF LIFE; SECONDARY PREVENTION; STEREOTACTIC RADIOSURGERY; STUDY DESIGN; SYSTEMIC THERAPY; WHOLE BRAIN RADIATION THERAPY;

ANTINEOPLASTIC AGENTS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS; PATIENT ADVOCACY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84857624491     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-011-0204-x     Document Type: Article

References (41)

1. D Rosner T Nemoto WW Lane 1986 Chemotherapy induces regression of brain metastases in breast carcinoma Cancer 58 832 9 3755076 10.1002/1097- 0142(19860815)58:4<832::AID-CNCR2820580404>3.0.CO;2-W 1:STN:280: DyaL283ksVOjtg%3D%3D (Pubitemid 16035278)
2. G Cocconi R Lottici G Bisagni, et al. 1990 Combination therapy with platinum and etoposide of brain metastases from breast carcinoma Cancer Invest 8 327 34 2207757 10.3109/07357909009012049 1:STN:280:DyaK3M%2FgtlGhtQ%3D%3D (Pubitemid 20352764)
3. Y Ushio N Arita T Hayakawa, et al. 1991 Chemotherapy of brain metastases from lung carcinoma: a controlled randomized study Neurosurgery 28 201 5 1997887 10.1227/00006123-199102000-00005 1:STN:280:DyaK3M7kvVOmtQ%3D%3D
4. W Boogerd O Dalesio EM Bais JJ van der Sande 1992 Response of brain metastases from breast cancer to systemic chemotherapy Cancer 69 972 80 1735089 10.1002/1097-0142(19920215)69:4<972::AID-CNCR2820690423>3.0.CO;2-P 1:STN:280:DyaK387js1ensA%3D%3D
5. V Franciosi G Cocconi M Michiara, et al. 1999 Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study Cancer 85 1599 605 10193952 10.1002/(SICI)1097-0142(19990401)85:7<1599: :AID-CNCR23>3.0.CO;2-# 1:CAS:528:DyaK1MXitlaqs7g%3D (Pubitemid 29152834)
6. PE Postmus H Haaxma-Reiche EF Smit, et al. 2000 Treatment of brain metastases of small-cell lung cancer: comparing teniposide and teniposide with whole-brain radiotherapy-a phase III study of the European Organization for the Research and Treatment of Cancer Lung Cancer Cooperative Group J Clin Oncol 18 3400 8 11013281 1:CAS:528:DC%2BD3cXnslWjsrw%3D
7. G Robinet P Thomas JL Breton, et al. 2001 Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Francais de Pneumo-Cancerologie (GFPC) Protocol 95-1 Ann Oncol 12 59 67 11249050 10.1023/A:1008338312647 1:STN:280:DC%2BD3Mzit1Ojug%3D%3D (Pubitemid 32162449)
8. PW Sperduto ST Chao PK Sneed, et al. 2010 Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients Int J Radiat Oncol Biol Phys 77 655 661 19942357 10.1016/j.ijrobp.2009.08.025 This extensive analysis provides a useful guide to prognosis for patients with newly diagnosed brain metastases from multiple primary sites
9. •• Sperduto PW, Kased N, Roberge D, et al.: Effect of tumor subtype on survival and the Graded Prognostic Assessment for patients with breast cancer and brain metastases. Int J Radiat Oncol Biol Phys 2011. This refinement of the GPA represents a new standard for prognostication and clinical trial stratification for patients with breast cancer brain metastases.
10. U Wilking E Karlsson L Skoog, et al. 2011 HER2 status in a population-derived breast cancer cohort: discordances during tumor progression Breast Cancer Res Treat 125 553 61 20628810 10.1007/s10549-010-1029-2 1:CAS:528:DC%2BC3cXhsFCqt73E
11. PS Steeg KA Camphausen QR Smith 2011 Brain metastases as preventive and therapeutic targets Nat Rev Cancer 11 352 363 21472002 10.1038/nrc3053 1:CAS:528:DC%2BC3MXksVCrtro%3D This review explores the latest scientific data to support the exploration of prevention of brain metastases
12. JS Wefel AK Saleeba AU Buzdar CA Meyers 2010 Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer Cancer 116 3348 56 20564075 10.1002/cncr.25098
13. CA Meyers JA Smith A Bezjak, et al. 2004 Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial J Clin Oncol 22 157 65 14701778 10.1200/JCO.2004.05.128 1:CAS:528:DC%2BD2cXpsVKhsrs%3D (Pubitemid 41095128)
14. PR Lockman RK Mittapalli KS Taskar, et al. 2010 Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer Clin Cancer Res 16 5664 78 20829328 10.1158/1078-0432.CCR-10- 1564 1:CAS:528:DC%2BC3cXhsFamtL3F
15. J Hoffmann I Fichtner M Lemm, et al. 2009 Sagopilone crosses the blood-brain barrier in vivo to inhibit brain tumor growth and metastases Neuro Oncol 11 158 66 18780814 10.1215/15228517-2008-072 1:CAS:528: DC%2BD1MXkvFentrY%3D
16. Freedman RA, Bullitt E, Sun L, et al.: A Phase II Study of Sagopilone (ZK 219477; ZK-EPO) in Patients with Breast Cancer and Brain Metastases. Clin Breast Cancer 2011.
17. LL Muldoon C Soussain K Jahnke, et al. 2007 Chemotherapy delivery issues in central nervous system malignancy: a reality check J Clin Oncol 25 2295 305 17538176 10.1200/JCO.2006.09.9861 1:CAS:528:DC%2BD2sXnsVShu7o%3D (Pubitemid 46954658)
18. YQ Li P Chen A Haimovitz-Friedman, et al. 2003 Endothelial apoptosis initiates acute blood-brain barrier disruption after ionizing radiation Cancer Res 63 5950 6 14522921 1:CAS:528:DC%2BD3sXnvVSisLw%3D (Pubitemid 37187496)
19. NE Schartz C Farges I Madelaine, et al. 2010 Complete regression of a previously untreated melanoma brain metastasis with ipilimumab Melanoma Res 20 247 50 20216240
20. FS Hodi DA Oble J Drappatz, et al. 2008 CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS Nat Clin Pract Oncol 5 557 61 18665147 10.1038/ncponc1183 1:CAS:528:DC%2BD1cXhtVGgt7fL
21. KA Margolin AM Di Giacomo M Maio 2010 Brain metastasis in melanoma: clinical activity of CTLA-4 antibody therapy Semin Oncol 37 468 472 21074062 10.1053/j.seminoncol.2010.09.014 1:CAS:528:DC%2BC3cXhsVWrtbfF A clear summary of the data that documents the activity of ipilimumab in brain metastases from melanoma
22. DPHO Lawrence DF McDermott, et al. 2010 Phase II trial of ipilimumab monotherapy in melanoma patients with brain metastases J Clin Oncol 28 15s (abstr 8523)
23. M Maio E Fonsatti A Burigo G Parmiani 2008 The Italian Network for Tumor Biotherapy (NIBIT). Sharing visions, goals and efforts at European level Tumori 94 179 81 18564604 (Pubitemid 351838823)
24. ME Hegi AC Diserens P Bady, et al. 2011 Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib-a phase II trial Mol Cancer Ther 10 1102 12 21471286 10.1158/1535-7163.MCT-11-0048 1:CAS:528:DC%2BC3MXnt1anurc%3D
25. DA Reardon E Galanis JF DeGroot, et al. 2011 Clinical trial end points for high-grade glioma: the evolving landscape Neuro Oncol 13 353 61 21310734 10.1093/neuonc/noq203
26. A Fujita S Fukuoka H Takabatake, et al. 2000 Combination chemotherapy of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with brain metastases from non-small cell lung cancer Oncology 59 291 5 11096340 10.1159/000012185 1:CAS:528:DC%2BD3cXovVersr4%3D
27. S Siena L Crino M Danova, et al. 2010 Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study Ann Oncol 21 655 61 19767314 10.1093/annonc/mdp343 1:STN:280:DC%2BC3c7isVGmsA%3D%3D
28. NF Marko RJ Weil 2011 Medical oncology: Patients with brain metastases in early-phase trials Nat Rev Clin Oncol 8 390 1 21587217 10.1038/nrclinonc.2011. 73
29. AM Tsimberidou K Letourneau S Wen, et al. 2011 Phase I clinical trial outcomes in 93 patients with brain metastases: the MD anderson cancer center experience Clin Cancer Res 17 4110 8 21415223 10.1158/1078-0432.CCR-10-3095 1:CAS:528:DC%2BC3MXnsFKguro%3D
30. PY Wen D Schiff TF Cloughesy, et al. 2011 It is time to include patients with brain tumors in phase I trials in oncology J Clin Oncol 29 3211 3213 21768451 10.1200/JCO.2011.36.6328 This manuscript clearly describes the rationale for including brain tumor patients in phase 1 trials in oncology
31. B Glimelius M Lahn 2011 Window-of-opportunity trials to evaluate clinical activity of new molecular entities in oncology Ann Oncol 22 1717 25 21239400 10.1093/annonc/mdq622 1:STN:280:DC%2BC3MjhsFGruw%3D%3D
32. H Aoyama H Shirato M Tago, et al. 2006 Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial JAMA 295 2483 91 16757720 10.1001/jama.295.21.2483 1:CAS:528:DC%2BD28XlsV2ltbo%3D (Pubitemid 43854963)
33. R Manon A O'Neill J Knisely, et al. 2005 Phase II trial of radiosurgery for one to three newly diagnosed brain metastases from renal cell carcinoma, melanoma, and sarcoma: an Eastern Cooperative Oncology Group study (E 6397) J Clin Oncol 23 8870 6 16314647 10.1200/JCO.2005.01.8747 (Pubitemid 46211534)
34. L Seymour SP Ivy D Sargent, et al. 2010 The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee Clin Cancer Res 16 1764 1769 20215557 10.1158/1078-0432.CCR- 09-3287 1:CAS:528:DC%2BC3cXjtFyhtbw%3D This NCI consensus recommendation helps to guide the design of phase 2 clinical trials
35. DA Berry 2010 Adaptive clinical trials: the promise and the caution J Clin Oncol 29 606 9 21172875 10.1200/JCO.2010.32.2685
36. DA Berry 2006 Bayesian clinical trials Nat Rev Drug Discov 5 27 36 16485344 10.1038/nrd1927 1:CAS:528:DC%2BD28Xmt1yqsw%3D%3D
37. AD Barker CC Sigman GJ Kelloff, et al. 2009 I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy Clin Pharmacol Ther 86 97 100 19440188 10.1038/clpt.2009.68 1:STN:280:DC%2BD1Mvis1Gjsg%3D%3D
38. C Printz 2010 BATTLE to personalize lung cancer treatment. Novel clinical trial design and tissue gathering procedures drive biomarker discovery Cancer 116 3307 8 20602437 10.1002/cncr.25493
39. DW Andrews CB Scott PW Sperduto, et al. 2004 Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial Lancet 363 1665 72 15158627 10.1016/S0140-6736(04)16250-8 (Pubitemid 38670323)
40. If you are newly diagnosed. 2011 [updated 2011; cited]; Available from: http://www.brainmetsbc.org/en/content/if-you-are-newly-diagnosed.
41. Mayer M. Brainmetsbc.org. 2011 [updated 2011; cited 2011 August]; Available from: http://www.brainmetsbc.org/.